MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    What assistive devices do people with Parkinson’s disease find most useful?

    H. Adams, C. Babbush, C. Kilbane (Cleveland, USA)

    Objective: To determine what everyday assistive devices were deemed most useful by people with Parkinson’s disease (PwP) and their caregivers. Background: Numerous helpful assistive devices…
  • 2024 International Congress

    Experiences of a personalised intervention to support self-management in PwP – PD-Care: Live Well with Parkinson’s

    T. Rookes, K. Kantilal, K. Walters, N. Kime, A. Kassavou, M. Younossi, WN. Tsang, P. Schartau, B. Gardner, N. Davies, A. Schrag (London, United Kingdom)

    Objective: 1) Evaluate acceptability and feasibility of the intervention2) Understand barriers and enablers to engagement and intervention improvement recommendations Background: We co-designed the ‘Live Well…
  • 2024 International Congress

    Sleep disorders in Parkinson’s disease

    M. Mirqosimova (Dushanbe, Tajikistan)

    Objective: to specify the clinical features of sleep disorders in patients with PD and their impact on quality of life indicators; assessment of the relationship…
  • 2024 International Congress

    Assembling a Cohort of Hyposmic Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention

    B. Mcmahon, L. Lemon, R. Dobkin, E. Brown, J. Dimos, M. Kuhl, L. Heathers (Baltimore, USA)

    Objective: The goal of this project was to amass a cohort of individuals with hyposmia to later invite them to participate in clinical trials for…
  • 2024 International Congress

    The 201 Trial in Untreated Parkinson’s Disease

    M. Werner, CW. Olanow, A. Mcgarry, C. Meyer, E. Mancino, C. Klint, J. Pellecchia (Atlanta, USA)

    Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…
  • 2024 International Congress

    Identifying Subjects with Dopamine Transporter Deficit in a Population-based Recruitment Strategy: Kassel Data of Healthy Brain Ageing

    S. Schade, K. Rege, C. Corinne, A. Garrido, T. Marques, P. Mahlknecht, S. Ghosh, R. Rawal, C. Pauly, T. Wicke, E. Lang, S. Schnell, S. Scaglione, H. Hakelberg, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer, D. Pilco (Kassel, Germany)

    Objective: To identify subjects with dopamine transporter (DaT) deficit being at high risk for prodromal PD. Background: Neurodegeneration and dopaminergic deficit in PD occur before the development…
  • 2024 International Congress

    Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial

    E. Mitchell (London, United Kingdom)

    Objective: Slow-SPEED-UK is a randomized controlled trial investigating the effects of an app-based exercise program on individuals at higher risk of Parkinson’s Disease (PD). Background:…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

    D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

    Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
  • 2024 International Congress

    Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model

    G. Tian, R. Zhou, J. Lu, W. Shi, R. Li, X. Guo (Xi'an, China)

    Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…
  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • #24752 (not found)
    • Effect of Aspartame on Parkinson’s Disease Progression and Severity
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley